Crescent Biopharma (CBIO)
Develops antibody medicines for solid tumors through bispecific and ADC programs.
$18.27
Pre-market−0.24 (−1.30%)
At close$18.51(+3.23%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
in 63 days
EPS estimate
−$0.67
Revenue estimate
$357.1K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Jul '25Nov '25Feb '26Apr '26Jul '26Nov '26
Reported−$0.11−$0.04−$4.93−$1.27−$4.01−$0.70−$0.74Pending
Estimate−$0.16−$0.05−$2.69−$1.01−$2.22−$0.85−$0.74−$0.67
Surprise+31.3%+20.0%−83.3%−25.7%−80.6%+17.6%−0.6%—
RevenueReportedEstimate
Feb '25May '25Jul '25Nov '25Feb '26Apr '26Jul '26Nov '26
Reported$54.1K———$10.8M$1.0M—Pending
Estimate————$10.0M$357.1K$357.1K$357.1K
Surprise————+8.4%+180.0%——
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.67 | — | — |
| Jul 2026 | −$0.74 | −$0.74 | −0.6% |
| Apr 2026 | −$0.85 | −$0.70 | +17.6% |
| Feb 2026 | −$2.22 | −$4.01 | −80.6% |
| Nov 2025 | −$1.01 | −$1.27 | −25.7% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Jul 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| Apr 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Jul 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.67 | — | — | $357.1K | — | — | — |
| Jul 30, 2026 | −$0.74 | −$0.74 | −0.6% | $357.1K | — | — | +1.7% |
| Apr 29, 2026 | −$0.85 | −$0.70 | +17.6% | $357.1K | $1.0M | +180.0% | +6.8% |
| Feb 26, 2026 | −$2.22 | −$4.01 | −80.6% | $10.0M | $10.8M | +8.4% | −2.1% |
| Nov 6, 2025 | −$1.01 | −$1.27 | −25.7% | — | — | — | +0.2% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Jul 31, 2025 | |||||||
| May 14, 2025 | |||||||
| Feb 13, 2025 | |||||||
| Nov 13, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 27, 2024 | |||||||
| Nov 3, 2023 | |||||||
| Aug 2, 2023 | |||||||
| May 3, 2023 | |||||||
| Mar 29, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 3, 2022 | |||||||
| Apr 28, 2022 | |||||||
| Mar 3, 2022 | |||||||
| Nov 2, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 3, 2021 | |||||||
| Mar 2, 2021 | |||||||
| Nov 6, 2020 | |||||||
| Jul 31, 2020 | |||||||
| May 1, 2020 | |||||||
| Feb 28, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 1, 2019 | |||||||
| May 2, 2019 | |||||||
| Mar 6, 2019 | |||||||
| Nov 2, 2018 | |||||||
| Aug 9, 2018 | |||||||
| May 3, 2018 | |||||||
| Mar 6, 2018 | |||||||
| Nov 8, 2017 | |||||||
| Aug 3, 2017 | |||||||
| May 8, 2017 | |||||||
| Mar 1, 2017 | |||||||
| Nov 4, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 4, 2016 | |||||||
| Feb 29, 2016 | |||||||
| Nov 12, 2015 | |||||||
| Aug 6, 2015 | |||||||